2012年1月11日，星期三
AstraZeneca today announced that it has entered into a three-year collaboration agreement with IMS Health, the leading provider of information, services and technology for the healthcare sector, to advance the use of real-world evidence based on observational and retrospective studies throughout Europe to inform the delivery of effective and cost-efficient healthcare.
The partnership with IMS Health will give AstraZeneca access to pre-existing anonymised electronic health records, which include clinical outcome, economic and treatment pattern data. In addition, the companies will jointly develop a customised research and data analysis platform. The information will provide a deeper insight into how medicines that are already on the market are working in real-world settings across Europe, painting a picture of unmet needs in the current standard of care and treatment patterns across a number of therapeutic areas, with an emphasis on chronic illnesses. The data will also be used to inform AstraZeneca’s discovery and clinical development programmes.
阿斯利康研发总裁马丁·麦凯（M欧洲杯微信买球artin Mackay）表示：“我们与IMS的合作是我们承诺了解我们的药物在现实世界中的影响的关键里程碑，而不是我们在对照临床试验中看到的。这种见解将帮助我们和医疗保健决策者改善疾病的治疗，并确保有效利用药物来最大程度地减少个人和医疗保健预算的负担。”
IMS Health现实证据解决方案副总裁乔恩·雷斯尼克（Jon Resnick）表示：“这项联合计划反映了关于全球卫生系统现实世界证据的变革性的共同观点。我们的独特信息资产，再加上我们的服务和技术能力，使IMS成为医疗组织的主要合作伙伴，以识别，整合和解释现实世界成果。我们很高兴与阿斯利康合作进行这项合作。”欧洲杯微信买球
The collaboration reflects the interest among healthcare decision-makers in examining the cost and effectiveness of new and existing medicines and health technologies to help allocate their increasingly limited resources more efficiently. Unlike controlled clinical trials, real-world evidence studies use observational data such as electronic medical records, claims information, patient registries and patient surveys. By evaluating the data associated with the delivery of care, ‘real-world’ analyses can demonstrate treatment impact on measurable outcomes such as hospital length of stay, readmissions, overall health status and total cost of care.
Today’s announcement builds on AstraZeneca’s existing ‘real-world’ data and research partnership with HealthCore in the US, the health outcomes research subsidiary of WellPoint.
The financial terms of the collaboration agreement are not disclosed.
注释编辑
About IMS Health
IMS Health is the leading provider of information, services and technology for the healthcare industry around the world. With a presence in more than 100 countries, the company draws on its global technology infrastructure and unique combination of in-depth, sophisticated analytics, on-shore and off-shore commercial services, and consulting platforms to help clients better understand the performance and value of medicines. Additional information is available athttp://www.imshealth.com
关于阿斯利康欧洲杯微信买球
欧洲杯微信买球阿斯利康（Astrazeneca）是一家全球创新驱动的生物制药业务，主要关注胃肠道，心血管，神经科学，呼吸和炎症，肿瘤学和感染性疾病的处方药的发现，开发和商业化。欧洲杯微信买球阿斯利康在100多个国家 /地区运营，其创新药物被全球数百万患者使用。有关更多信息，请访问：www.vivelima.com
CONTACTS
媒体查询
Esra Erkal-Paler +44 20 7604 8030（24小时）
Isabelle Jouin +44 20 7604 8031（24小时）
阿比盖尔男爵+44 20 7604 8034（24小时）
Investor Enquiries UK
James Ward-Lilley +44 20 7604 8122
KarlHård+44 20 7604 8123暴民：+44 7789 654364
Nicklas Westerholm +44 20 7604 8124 mob: +44 7585 404950
Investor Enquiries US
Ed Seage +1 302 886 4065 mob: +1 302 373 1361
Jorgen Winroth +1 212 579 0506暴民：+1 917 612 4043